41 research outputs found
Semi-Automated DIRSIG scene modeling from 3D lidar and passive imagery
The Digital Imaging and Remote Sensing Image Generation (DIRSIG) model is an established, first-principles based scene simulation tool that produces synthetic multispectral and hyperspectral images from the visible to long wave infrared (0.4 to 20 microns). Over the last few years, significant enhancements such as spectral polarimetric and active Light Detection and Ranging (lidar) models have also been incorporated into the software, providing an extremely powerful tool for multi-sensor algorithm testing and sensor evaluation. However, the extensive time required to create large-scale scenes has limited DIRSIGâs ability to generate scenes âon demand.â To date, scene generation has been a laborious, time-intensive process, as the terrain model, CAD objects and background maps have to be created and attributed manually. To shorten the time required for this process, this research developed an approach to reduce the man-in-the-loop requirements for several aspects of synthetic scene construction. Through a fusion of 3D lidar data with passive imagery, we were able to semi-automate several of the required tasks in the DIRSIG scene creation process. Additionally, many of the remaining tasks realized a shortened implementation time through this application of multi-modal imagery. Lidar data is exploited to identify ground and object features as well as to define initial tree location and building parameter estimates. These estimates are then refined by analyzing high-resolution frame array imagery using the concepts of projective geometry in lieu of the more common Euclidean approach found in most traditional photogrammetric references. Spectral imagery is also used to assign material characteristics to the modeled geometric objects. This is achieved through a modified atmospheric compensation applied to raw hyperspectral imagery. These techniques have been successfully applied to imagery collected over the RIT campus and the greater Rochester area. The data used include multiple-return point information provided by an Optech lidar linescanning sensor, multispectral frame array imagery from the Wildfire Airborne Sensor Program (WASP) and WASP-lite sensors, and hyperspectral data from the Modular Imaging Spectrometer Instrument (MISI) and the COMPact Airborne Spectral Sensor (COMPASS). Information from these image sources was fused and processed using the semi-automated approach to provide the DIRSIG input files used to define a synthetic scene. When compared to the standard manual process for creating these files, we achieved approximately a tenfold increase in speed, as well as a significant increase in geometric accuracy
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Improving outcomes in multiple myeloma will involve not only development of new therapies but also better use of existing treatments. We performed RNA sequencing on samples from newly diagnosed patients enrolled in the phase 2 PADIMAC (Bortezomib, Adriamycin, and Dexamethasone Therapy for Previously Untreated Patients with Multiple Myeloma: Impact of Minimal Residual Disease in Patients with Deferred ASCT) study. Using synthetic annealing and the large margin nearest neighbor algorithm, we developed and trained a 7-gene signature to predict treatment outcome. We tested the signature in independent cohorts treated with bortezomib- and lenalidomide-based therapies. The signature was capable of distinguishing which patients would respond better to which regimen. In the CoMMpass data set, patients who were treated correctly according to the signature had a better progression-free survival (median, 20.1 months vs not reached; hazard ratio [HR], 0.40; confidence interval [CI], 0.23-0.72; P = .0012) and overall survival (median, 30.7 months vs not reached; HR, 0.41; CI, 0.21-0.80; P = .0049) than those who were not. Indeed, the outcome for these correctly treated patients was noninferior to that for those treated with combined bortezomib, lenalidomide, and dexamethasone, arguably the standard of care in the United States but not widely available elsewhere. The small size of the signature will facilitate clinical translation, thus enabling more targeted drug regimens to be delivered in myeloma.Wellcome Trust, Bloodwise, Cancer Research UK
Regioselective Synthesis of Benzimidazolones via Cascade CâN Coupling of Monosubstituted Ureas
A direct method for the regioselective construction of benzimidazolones is reported wherein a single palladium catalyst is employed to couple monosubstituted urea substrates with differentially substituted 1,2-dihaloaromatic systems. In this method, the catalyst is able to promote a cascade of two discrete chemoselective CâN bond-forming processes that allows the highly selective and predictable formation of complex heterocycles from simple, readily available starting materials.National Institutes of Health (U.S.) (Award GM58160)National Institutes of Health (U.S.) (Award GM099817)Lanxess CorporationMassachusetts Institute of Technology. Undergraduate Research Opportunities Progra
Pattern of Relapse and Treatment Response in WNT- Activated Medulloblastoma
Over the past decade, wingless-activated (WNT) medulloblastoma has been identified as a candidate for therapy de-escalation based on excellent survival; however, a paucity of relapses has precluded additional analyses of markers of relapse. To address this gap in knowledge, an international cohort of 93 molecularly confirmed WNT MB was assembled, where 5-year progression-free survival is 0.84 (95%, 0.763-0.925) with 15 relapsed individuals identified. Maintenance chemotherapy is identified as a strong predictor of relapse, with individuals receiving high doses of cyclophosphamide or ifosphamide having only one very late molecularly confirmed relapse (p = 0.032). The anatomical location of recurrence is metastatic in 12 of 15 relapses, with 8 of 12 metastatic relapses in the lateral ventricles. Maintenance chemotherapy, specifically cumulative cyclophosphamide doses, is a significant predictor of relapse across WNT MB. Future efforts to de-escalate therapy need to carefully consider not only the radiation dose but also the chemotherapy regimen and the propensity for metastatic relapses
Recommended from our members
Managing the whole landscape: historical, hybrid, and novel ecosystems
The reality confronting ecosystem managers today is one of heterogeneous, rapidly transforming landscapes,
particularly in the areas more affected by urban and agricultural development. A landscape management
framework that incorporates all systems, across the spectrum of degrees of alteration, provides a fuller set of
options for how and when to intervene, uses limited resources more effectively, and increases the chances of
achieving management goals. That many ecosystems have departed so substantially from their historical trajectory
that they defy conventional restoration is not in dispute. Acknowledging novel ecosystems need not
constitute a threat to existing policy and management approaches. Rather, the development of an integrated
approach to management interventions can provide options that are in tune with the current reality of rapid
ecosystem change
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biological implications of TERT mutations in medulloblastoma have not been described. Hence, we sought to describe these mutations and their impact in a subgroup-specific manner. We analyzed the TERT promoter by direct sequencing and genotyping in 466 medulloblastomas. The mutational distributions were determined according to subgroup affiliation, demographics, and clinical, prognostic, and molecular features. Integrated genomics approaches were used to identify specific somatic copy number alterations in TERT promoter-mutated and wild-type tumors. Overall, TERT promoter mutations were identified in 21 % of medulloblastomas. Strikingly, the highest frequencies of TERT mutations were observed in SHH (83 %; 55/66) and WNT (31 %; 4/13) medulloblastomas derived from adult patients. Group 3 and Group 4 harbored this alteration in <5 % of cases and showed no association wit
Cytogenetic Prognostication Within Medulloblastoma Subgroups
PURPOSE: Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, and histologic variant. Stark prognostic and genetic differences among the four subgroups suggest that subgroup-specific molecular biomarkers could improve patient prognostication. PATIENTS AND METHODS: Molecular biomarkers were identified from a discovery set of 673 medulloblastomas from 43 cities around the world. Combined risk stratification models were designed based on clinical and cytogenetic biomarkers identified by multivariable Cox proportional hazards analyses. Identified biomarkers were tested using fluorescent in situ hybridization (FISH) on a nonoverlapping medulloblastoma tissue microarray (n = 453), with subsequent validation of the risk stratification models. RESULTS: Subgroup information improves the predictive accuracy of a multivariable survival model compared with clinical biomarkers alone. Most previously published cytogenetic biomarkers are only prognostic within a single medulloblastoma subgroup. Profiling six FISH biomarkers (GLI2, MYC, chromosome 11 [chr11], chr14, 17p, and 17q) on formalin-fixed paraffin-embedded tissues, we can reliably and reproducibly identify very low-risk and very high-risk patients within SHH, Group 3, and Group 4 medulloblastomas. CONCLUSION: Combining subgroup and cytogenetic biomarkers with established clinical biomarkers substantially improves patient prognostication, even in the context of heterogeneous clinical therapies. The prognostic significance of most molecular biomarkers is restricted to a specific subgroup. We have identified a small panel of cytogenetic biomarkers that reliably identifies very high-risk and very low-risk groups of patients, making it an excellent tool for selecting patients for therapy intensification and therapy de-escalation in future clinical trials
The Helicobacter pylori Genome Project : insights into H. pylori population structure from analysis of a worldwide collection of complete genomes
Helicobacter pylori, a dominant member of the gastric microbiota, shares co-evolutionary history with humans. This has led to the development of genetically distinct H. pylori subpopulations associated with the geographic origin of the host and with differential gastric disease risk. Here, we provide insights into H. pylori population structure as a part of the Helicobacter pylori Genome Project (HpGP), a multi-disciplinary initiative aimed at elucidating H. pylori pathogenesis and identifying new therapeutic targets. We collected 1011 well-characterized clinical strains from 50 countries and generated high-quality genome sequences. We analysed core genome diversity and population structure of the HpGP dataset and 255 worldwide reference genomes to outline the ancestral contribution to Eurasian, African, and American populations. We found evidence of substantial contribution of population hpNorthAsia and subpopulation hspUral in Northern European H. pylori. The genomes of H. pylori isolated from northern and southern Indigenous Americans differed in that bacteria isolated in northern Indigenous communities were more similar to North Asian H. pylori while the southern had higher relatedness to hpEastAsia. Notably, we also found a highly clonal yet geographically dispersed North American subpopulation, which is negative for the cag pathogenicity island, and present in 7% of sequenced US genomes. We expect the HpGP dataset and the corresponding strains to become a major asset for H. pylori genomics